T + T – Normal size
The activities of the 4th Abu Dhabi Neurology Conference, which concludes today, Sunday, in Abu Dhabi, revealed the two newest drugs for treating Alzheimer’s in the world (Leqembi) and (Kisunla).
“The discussions at the conference, which was organised by the Emirates Neurological Society under the patronage of Abu Dhabi Health Services Company (SEHA), a subsidiary of the Pure Health Group, and the United Arab Emirates University, focused on the latest research and developments in multiple sclerosis, the latest medications in this field, types of headaches and their diagnosis using the latest treatment protocols, in addition to special discussions on Alzheimer’s disease,” said Dr. Suhail Abdullah Al Rukun, Consultant Neurologist, President of the Emirates Neurological Society, and member of the conference’s organising committee.
He added: “The conference witnessed the unveiling and announcement of the two latest drugs in the world for treating Alzheimer’s, which were made available in the UAE and approved by the US Food and Drug Administration (FDA) during the years 2023-2024,” explaining that the drugs that were unveiled today help and contribute to reducing the development of Alzheimer’s disease by removing amyloid protein from the brain, which reduces the deterioration of the patient’s condition.
He explained that the new drug “Kesonla” is a drug from the class of antibodies to the amyloid protein deposited in the brain in Alzheimer’s disease, and is given every month for a long period. It is the third anti-amyloid drug approved for use after the drugs “Adiohelm” and “Lekimbi”.
He pointed out that these two medications are administered by neurologists specializing in Alzheimer’s disease after conducting head x-rays and confirming the presence of amyloid in the tissues or cerebrospinal fluid through precise and specific examinations in this regard, noting that these treatments are only given to patients with mild cognitive impairment and in the early stages of Alzheimer’s disease.
He stressed that the presence and availability of such medicines in the UAE enhances the distinguished healthcare in the country, which provides an opportunity for a very large number of patients awaiting treatments for Alzheimer’s disease.
During the second day, the conference organized a number of workshops targeting trainee neurologists, and hosted Professor Dr. Michael Stroop, one of the pioneers in neuro-ophthalmology at Ludwig Maximilian University in Germany, who presented two scientific courses for attending doctors and specialists in this field, on the latest methods of diagnosing and treating eye disorders.
Dr. Hidaya Ali Ansari, a specialist at the Imaging Institute at Cleveland Clinic Abu Dhabi, presented workshops on the hidden features of multiple sclerosis and focused on unnoticed disability, while Dr. Nasser Al Zubaidi, a consultant psychiatrist at Khalifa City Health Center, presented a workshop on managing the behavior of people with dementia.
The conference aimed to shed light on the latest methods and treatments for various neurological diseases, and the most important research findings of international universities and pharmaceutical companies in terms of modern medical products.
